Who are Subutex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Subutex, Buprenorphine (Subutex), PBO-N/PBO-B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/buprenorphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Subutex — Competitive Intelligence Brief

Subutex (BUPRENORPHINE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Partial Opioid Agonist. Area: Neuroscience.

marketed Partial Opioid Agonist mu-opioid receptor, kappa-opioid receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Subutex (BUPRENORPHINE) — Purdue Pharma Lp. Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Subutex TARGET	BUPRENORPHINE	Purdue Pharma Lp	marketed	Partial Opioid Agonist	mu-opioid receptor, kappa-opioid receptor	1981-01-01
Subutex	Buprenorphine Hydrochloride	Indivior	marketed	partial opioid agonist	mu-opioid receptor, kappa-opioid receptor	1981-01-01
Buprenorphine (Subutex)	Buprenorphine (Subutex)	Indivior Inc.	marketed	Partial opioid agonist	Mu-opioid receptor (μ-OR)
PBO-N/PBO-B	PBO-N/PBO-B	Alkermes, Inc.	phase 3	partial opioid agonist	mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-31 — Subutex · 8236755 · Formulation · US
2027-01-10 — Subutex · 8236292 · Formulation · US
2027-07-23 — Subutex · 8147866 · Formulation · US
2027-07-23 — Subutex · 9655843 · Formulation · US
2031-06-06 — Subutex · 9782402 · Formulation · US
2031-06-06 — Subutex · 9827241 · Formulation · US
2031-06-06 — Subutex · 10198218 · Method of Use · US
2031-06-06 — Subutex · 10592168 · Method of Use · US
2031-06-06 — Subutex · 9498432 · Formulation · US
2031-06-06 — Subutex · 9272044 · Method of Use · US
2031-06-25 — Subutex · 10558394 · Formulation · US
2031-09-05 — Subutex · 8975270 · Formulation · US
2032-01-06 — Subutex · 8921387 · Formulation · US
2032-07-26 — Subutex · 11135215 · Formulation · US
2032-07-26 — Subutex · 12318379 · Formulation · US
2032-07-26 — Subutex · 12161640 · Formulation · US
2032-07-26 — Subutex · 11110084 · Formulation · US
2032-07-26 — Subutex · 10912772 · Method of Use · US
2032-07-26 — Subutex · 9937164 · Formulation · US
2032-12-21 — Subutex · 9901539 · Method of Use · US
2035-11-06 — Subutex · 11000520 · Method of Use · US
2035-11-06 — Subutex · 11839611 · Method of Use · US
2038-06-22 — Subutex · 10646484 · Method of Use · US

Sponsor landscape (Partial Opioid Agonist class)

Purdue Pharma Lp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Subutex — Competitive Intelligence Brief. https://druglandscape.com/ci/buprenorphine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab